<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="78837">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01789346</url>
  </required_header>
  <id_info>
    <org_study_id>C-12-EV3</org_study_id>
    <nct_id>NCT01789346</nct_id>
  </id_info>
  <brief_title>Pilot Study of a Novel 532nm KTP Laser for the Treatment of Fresh Surgical Scars</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cutera Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cutera Inc.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of the 532nm potassium
      titanyl phosphate (KTP) laser in comparison with the 595nm pulsed-dye laser (PDL) for the
      treatment of fresh surgical scars.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2013</start_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Comparison of percentage improvement in surgical scar between treatment (532nm KTP laser) and active control (595nm PDL) treatment arms.</measure>
    <time_frame>12-weeks post-final laser treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Scar</condition>
  <condition>Surgical Scar</condition>
  <condition>Cicatrix</condition>
  <condition>Cicatrix, Hypertrophic</condition>
  <condition>Keloid</condition>
  <arm_group>
    <arm_group_label>532nm KTP laser</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cutera ExcelV 532nm KTP laser</description>
  </arm_group>
  <arm_group>
    <arm_group_label>595nm PDL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cynosure Cynergy 595nm pulsed-dye laser</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>532nm potassium titanyl phosphate (KTP) laser</intervention_name>
    <arm_group_label>532nm KTP laser</arm_group_label>
    <other_name>ExcelV laser</other_name>
    <other_name>Cutera ExcelV</other_name>
    <other_name>Excel V</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>595nm pulsed-dye laser (PDL)</intervention_name>
    <arm_group_label>595nm PDL</arm_group_label>
    <other_name>Cynosure Cynergy</other_name>
    <other_name>Cynergy laser</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fitzpatrick Skin Type I - IV

          -  Has postoperative linear scar(s) which is one to twelve months post-surgery.

          -  Having one scar that measures a minimum of 5 cm in length or two scars (bilateral)
             each measure a minimum of 2 cm in length.

          -  Be in good health.

          -  Must agree not to undergo any other procedure for the treatment of scar during the
             study.

          -  Willing to refrain from excess sun exposure and willing to wear sunscreen on the
             treated scar during the study (including the follow-up period).

          -  Post-menopausal or surgically sterilized, or using a medically acceptable form of
             birth control at least 3 months prior to enrollment and during the entire course of
             the study.

        Exclusion Criteria:

          -  Participation in a study of another device or drug within 6 months prior to
             enrollment or during the study.

          -  Having received any prior treatment for the target surgical scar.

          -  Pregnant and/or breastfeeding.

          -  Significant concurrent illness, malignant tumors in the target area, acute or chronic
             skin infection/inflammation, currently using immunosuppressive medications or
             currently undergoing systemic chemotherapy.

          -  Current use of any medication known to increase sensitivity to light or taking
             prescription anticoagulation medication.

          -  History of abnormal or delayed wound healing, keloid formation or pigmentary
             disorders, particularly tendency for hyper- or hypo-pigmentation.

          -  History of malignant skin disease, immune deficiency disorders, seizure disorders due
             to light, or diseases stimulated by heat, unless prophylactic measures taken prior to
             treatment.

          -  Systemic use of isotretinoin within 6 months or corticosteroids within 12 months of
             study participation.

          -  Anytime in life, had used gold therapy (gold salts) for disorders such as
             rheumatologic disease or lupus.

          -  Current smoker or history of smoking within 12 months of study participation.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Washington Institute of Dermatologic Laser Surgery</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 27, 2013</lastchanged_date>
  <firstreceived_date>February 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Scar</keyword>
  <keyword>Scars</keyword>
  <keyword>Surgical Scar</keyword>
  <keyword>Surgical Scars</keyword>
  <keyword>Cicatrix</keyword>
  <keyword>Hypertrophic Cicatrix</keyword>
  <keyword>Keloid</keyword>
  <keyword>Hypertrophic Scar</keyword>
  <keyword>Surgical Incision</keyword>
  <keyword>Scarring</keyword>
  <keyword>Abdominoplasty</keyword>
  <keyword>Tummy Tuck</keyword>
  <keyword>Augmentation Mammoplasty</keyword>
  <keyword>Breast Augmentation</keyword>
  <keyword>Thyroidectomy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Keloid</mesh_term>
    <mesh_term>Cicatrix, Hypertrophic</mesh_term>
    <mesh_term>Cicatrix</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
